| Related Articles |
Evaluation of ceftolozane/tazobactam activity against phylogenetically diverse Clostridium difficile strains.
Antimicrob Agents Chemother. 2015 Aug 17;
Authors: Gonzalez MD, Wallace MA, Hink T, Dubberke ER, Burnham CD
Abstract
Ceftolozane/tazobactam (C/T) is approved for treatment of complicated intra-abdominal and urinary tract infections; C/T has variable activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of C. difficile isolates, and report uniformly high minimum inhibitory concentrations (≥256 μg/mL) to C/T.
PMID: 26282409 [PubMed - as supplied by publisher]